QuickCool AB (publ) signs distribution agreement for United Kingdom and Ireland
QuickCool AB (publ) (”QuickCool”) has signed distribution agreement for United Kingdom and Ireland with Leib Medical Ltd, with is head office in Belfast, but that already has a well-established sales network in the region. This is QuickCool’s first distribution agreement. Preparatory sales activities start immediately, but no sales will occur until after the QuickCool© SYSTEM has acquired the CE-mark later this years. At least two QuickCool© SYSTEMs expect to be sold during 2018.
QuickCool, that develops a patented intranasal cooling solution for patients who have suffered from sudden cardiac arrest, has signed its first distribution agreement for United Kingdom and Ireland, with Leib Medical Ltd. This is a most significant, first agreement for some of the world’s most important markets.
”We gain access to a growing market within Target Temperature Management (TTM) that use cooling as praxis for the treatment of sudden cardiac arrest patients. There is a large installed base that can be immediately addressed, since many of the existing systems need to be replaced each year. Sales-, marketing- and training material will be refined and reused in other English speaking markets. The favourable price levels, already established network of Key Opinion Leaders (KOLs) and end-users at ICUs, and Leib Medical’s belief in the QuickCool© SYSTEM, are other advantages”, says Fredrik Radencrantz, CEO at QuickCool.”
Leib Medical was founded about two years ago by Robert Bailie who has worked with MedTech products the past 30 years or so, of which most as a distributor of well-known international brands, until the company was acquired. Leib Medical has an existing and well established network of customers to whom complementing products are currently sold.
“We are very pleased to work with QuickCool’s innovative cooling solution and are looking forward to develop the presence in the market place”, Robert Bailie, CEO at Leib Medical Ltd, says. “QuickCool’s solution fits perfectly into our strategy of expanding our market share within the area of ICUs. We are looking forward to introduce the QuickCool© SYSTEM both in the United Kingdom and Ireland. The ease-of-use in combination with the sense of high quality appealed to us. We are looking forward to a long and fruitful partnership”.
About Leib Medical Ltd.
Leib Medical Ltd., is an Irish owned, family business, focused on bringing innovative products, that enhance the procedural care, given by doctors and nurses in our hospitals. The purchase of any product, from Leib Medical, is the beginning of a long-term partnership with our commitment to our customers, to provide premium clinical & technical support.
For more information, please contact:
Fredrik Radencrantz, VD
Telefon: 046-286 38 40
This information is such that QuickCool AB is required to make public in accordance with the EU’s market abuse regulation (MAR) and the Swedish Securities Market Act. The information was made publicly available by the Company’s contact person on 02 July, 2018.
Quickcool is a Swedish medical technology company, whose business concept is to save lives and prevent brain damage in acute ischemia (Inadequate blood supply to the brain) by developing and providing a unique and globally patented cooling system, the Quickcool SYSTEM. Quickcool is active in the fast-growing market, Targeted Temperature Management (TTM), for brain-protective cooling treatment of patients with e.g. acute cardiac arrest and stroke. QuickCool’s solution protects the brain by cooling in the nasal cavity and thus takes advantage of the innate heat exchanger in the nose. QuickCool’s Intranasal method offers gentle and uninterrupted cooling treatment for sedated patients. Quickcool is listed on Spotlight Stock Market and conducts its business at Ideon Science Park in Lund. For more Information, please refer to www.quickcool.se